Quick Answer
Why cancer increases clot risk, how thrombosis is treated, and when to seek emergency care.
Medically reviewed by Dr. Sachita Baniya • NMC 20158 • Kathmandu Neurology Clinic & Cognitive Center
Cancer-associated thrombosis is a venous blood clot — usually deep vein thrombosis or pulmonary embolism — occurring in a person with cancer. It is common, sometimes silent and potentially life-threatening.
Why cancer increases clot risk
Cancer activates the clotting system. Surgery, hospitalisation, immobility, central venous catheters and some cancer treatments add further risk. Myeloma regimens that include immunomodulatory drugs carry a particularly well-recognised clot risk.
Symptoms of DVT
- Swelling of one leg
- Pain, tenderness or warmth
- Redness or discoloration
- Worsening discomfort when walking
Symptoms of pulmonary embolism
- Sudden breathlessness
- Chest pain, worse on breathing
- Fast heart rate
- Coughing blood
- Fainting or dizziness
Pulmonary embolism is an emergency. Call for urgent help.
Treatment
Anticoagulation is the main treatment. Low-molecular-weight heparin, direct oral anticoagulants and warfarin are selected according to cancer type, kidney function, platelet count, drug interactions and bleeding risk. Duration is usually at least three to six months and longer in active cancer.
Prevention
Selected hospitalised and ambulatory patients receive prophylaxis. In myeloma, clot risk is assessed before starting immunomodulatory therapy. Early mobilisation, hydration and catheter care also help.
What to discuss with your team
- Is my cancer or treatment associated with a high clot risk?
- Do I need prophylaxis?
- Which anticoagulant is safest for me?
- What are the warning signs of bleeding?
The bottom line
Clots are a recognised complication of cancer. Knowing the symptoms and raising them promptly can be life-saving.
Frequently asked questions
Answers reviewed by Dr. Jitendra Prasad Yadav • MBBS, MD (Internal Medicine), FICN (Neurology), FCNV, FIHM • NMC 8029
Cancer activates clotting pathways, and surgery, hospitalisation, catheters and some treatments add further risk.
Usually at least three to six months, and longer in active cancer. The plan is reviewed as cancer treatment changes.
Yes. Recurrence risk depends on the provoking factor and duration of anticoagulation. Long-term review is important.
More: All FAQs → · Ask Dr. Jitendra →
Related articles
CAR-T Cell Therapy: What Patients Should Know
CAR-T therapy is a cellular treatment for selected blood cancers. Learn how it works, who may be eligible and what monitoring involves.
Molecular Testing in Blood Cancer: What the Results Mean
Cytogenetics, FISH, PCR and next-generation sequencing guide diagnosis, risk and treatment in blood cancers.
Blood Cancer Symptoms: When to See a Haematologist
Unexplained bruising, persistent fatigue, swollen lymph nodes or repeated infections can be early signs of a blood disorder. Here is when to seek a haematology opinion.
Medical Disclaimer
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
References & Review
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
- International Classification of Headache Disorders, 3rd edition (ICHD-3).
- Harrison's Principles of Internal Medicine — Neurology sections.
- American Academy of Neurology guidelines for selected conditions (where applicable).
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.